Since the publication in 1998 of the articles by the UK Prospective Diabetes Study (UKPDS) group, guidelines for the management and treatment of type II diabetes have been standardized. When applied to an end-of-life population, these international recommendations do not have any scientific justification and go against quality-of-life goals promoted by hospice and palliative care. The aim is to demonstrate this in the current article.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
2.
UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
3.
The Action to Control Cardiovascular Risk in Diabetes Study (ACCORD) Group.Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
4.
The ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
5.
Gaede P., Vedel P., Larsen N., Parving HH, Pederson O.Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med. 2003;348(5):383-393.
